John B Liao1, Yuen Yee Yip2, Elizabeth M Swisher1, Kathy Agnew1, Karl Erik Hellstrom2, Ingegerd Hellstrom3. 1. Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA. 2. Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA. 3. Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA. Electronic address: ihellstr@u.washington.edu.
Abstract
OBJECTIVES: To measure HE4 levels in urine from normal donors, patients with LMP tumors and ovarian cancer patients and to correlate levels with clinical factors in ovarian cancer patients. METHODS: Archived samples from controls, patients with LMP tumors and ovarian cancer were tested using commercial assays, including serially collected serum and urine samples from women treated for stage III/IV serous ovarian cancer. RESULTS: Five of 6 patients with stage I/II and 26 of 36 stage III/IV serous ovarian cancer patients had HE4-positive urines, similar to serum samples (4 of 5 stage I/II and 26 of 34 stage III/IV) when tested at the same level of specificity (95%). Urine HE4 was more sensitive in LMP tumors: 9 of 32 urines (28%) HE4-positive versus 3 of 68 sera (4.4%, p=0.002). Mean levels of serum CA125 and HE4 decreased comparably in patients during initial treatment regardless of their primary platinum response, but mean urine HE4 levels decreased only 7% in primary platinum resistant patients while decreasing 68% in those who were sensitive. By 7months after diagnosis, urine HE4 levels were higher in primary platinum resistant patients compared to those who proved to be sensitive (p=0.051) and persisted 12months after diagnosis (p=0.014). HE4 values in urine also became positive in advance of clinical recurrence in several women while serum HE4 and serum CA-125 remained normal. CONCLUSIONS: Measuring HE4 in urine complements serum assays for the detection of ovarian cancer and may allow identification of patients at high risk for primary platinum resistance.
OBJECTIVES: To measure HE4 levels in urine from normal donors, patients with LMP tumors and ovarian cancerpatients and to correlate levels with clinical factors in ovarian cancerpatients. METHODS: Archived samples from controls, patients with LMP tumors and ovarian cancer were tested using commercial assays, including serially collected serum and urine samples from women treated for stage III/IV serous ovarian cancer. RESULTS: Five of 6 patients with stage I/II and 26 of 36 stage III/IV serous ovarian cancerpatients had HE4-positive urines, similar to serum samples (4 of 5 stage I/II and 26 of 34 stage III/IV) when tested at the same level of specificity (95%). Urine HE4 was more sensitive in LMP tumors: 9 of 32 urines (28%) HE4-positive versus 3 of 68 sera (4.4%, p=0.002). Mean levels of serum CA125 and HE4 decreased comparably in patients during initial treatment regardless of their primary platinum response, but mean urine HE4 levels decreased only 7% in primary platinum resistant patients while decreasing 68% in those who were sensitive. By 7months after diagnosis, urine HE4 levels were higher in primary platinum resistant patients compared to those who proved to be sensitive (p=0.051) and persisted 12months after diagnosis (p=0.014). HE4 values in urine also became positive in advance of clinical recurrence in several women while serum HE4 and serum CA-125 remained normal. CONCLUSIONS: Measuring HE4 in urine complements serum assays for the detection of ovarian cancer and may allow identification of patients at high risk for primary platinum resistance.
Authors: Ingegerd Hellstrom; Patrick J Heagerty; Elizabeth M Swisher; Pu Liu; Jade Jaffar; Kathy Agnew; Karl Erik Hellstrom Journal: Cancer Lett Date: 2010-04-08 Impact factor: 8.679
Authors: Bin Ye; Steven Skates; Samuel C Mok; Nora K Horick; Helene F Rosenberg; Allison Vitonis; Dale Edwards; Patrick Sluss; Won K Han; Ross S Berkowitz; Daniel W Cramer Journal: Clin Cancer Res Date: 2006-01-15 Impact factor: 12.531
Authors: K Ono; T Tanaka; T Tsunoda; O Kitahara; C Kihara; A Okamoto; K Ochiai; T Takagi; Y Nakamura Journal: Cancer Res Date: 2000-09-15 Impact factor: 12.701
Authors: Elena Ioana Braicu; Radoslav Chekerov; Rolf Richter; Carmen Pop; Mani Nassir; Hanna Loefgren; Florin Stamatian; Mustafa Zelal Muallem; Christina Hall; Christina Fotopoulou; Jalid Sehouli; Klaus Pietzner Journal: Ann Surg Oncol Date: 2013-11-12 Impact factor: 5.344
Authors: Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates Journal: Gynecol Oncol Date: 2008-10-12 Impact factor: 5.482
Authors: Nicole S Anderson; Yira Bermudez; Donna Badgwell; Ren Chen; Santo V Nicosia; Robert C Bast; Patricia A Kruk Journal: Gynecol Oncol Date: 2008-11-12 Impact factor: 5.482
Authors: Pierluigi Giampaolino; Virginia Foreste; Luigi Della Corte; Claudia Di Filippo; Giuseppe Iorio; Giuseppe Bifulco Journal: Gland Surg Date: 2020-08
Authors: Dagmar Quandt; Hans Dieter Zucht; Arno Amann; Anne Wulf-Goldenberg; Carl Borrebaeck; Michael Cannarile; Diether Lambrechts; Herbert Oberacher; James Garrett; Tapan Nayak; Michael Kazinski; Charles Massie; Heidi Schwarzenbach; Michele Maio; Robert Prins; Björn Wendik; Richard Hockett; Daniel Enderle; Mikkel Noerholm; Hans Hendriks; Heinz Zwierzina; Barbara Seliger Journal: Oncotarget Date: 2017-07-18